TG Therapeutics, Inc. (NASDAQ:TGTX) shares climbed in Tuesday’s extended trading after the company released its preliminary fourth quarter revenue estimates and provided an optimistic outlook for 2026. Here’s a look at the details. TGTX stock is climbing. See the chart and price action here. TG Therapeutics said it expects Briumvi U.S. net product revenue to be approximately $182 million and$594 million for the fourth quarter and full year of 2025, respectively, with total global full year 2025 revenue of ...